Advertisement

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

  • Michael SoykaEmail author
  • Oliver Pogarell
Übersichten
  • 23 Downloads

Zusammenfassung

Die Opioidsubstitution mit Methadon oder Buprenorphin ist eine anerkannte, weltweit praktizierte First-line-Behandlung der Opioidabhängigkeit. Neben dem in Deutschland bereits verfügbaren wöchentlich oder monatlich subkutan injizierbaren Buprenorphin Depot CAM 2038 (Buvidal®) stehen mit dem monatlich zu applizierenden Depotpräparat RBP-6000 (Sublocade™) und dem 6 Monate wirkenden Buprenorphin-Depot-Implantat (Probuphine™) demnächst wahrscheinlich mehrere langzeitwirksame Buprenorphinformulierungen zur Verfügung. Der bisherige Wissensstand und mögliche Einsatzgebiete dieser Präparate werden diskutiert.

Schlüsselwörter

Opioide Opioidabhängigkeit Pharmakologie Substitutionsbehandlung Sicherheit 

New slow-release buprenorphine formulations for optimization of opioid substitution

Abstract

Opioid maintenance treatment with methadone or buprenorphine is an established first-line treatment for opioid dependence. In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal®), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade™) and a 6-month buprenorphine depot implant (Probuphine™). Basic pharmacological and clinical data of these three medications are given and possible clinical applications are discussed.

Keywords

Opioids Opioid dependence Pharmacology Opioid maintenance therapy Safety 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Soyka und O. Pogarell geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F (2017) Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 34:560–575CrossRefGoogle Scholar
  2. 2.
    Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S (2008) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 4:CD5031Google Scholar
  3. 3.
    Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 9:CD5031Google Scholar
  4. 4.
    Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 10:CD4147Google Scholar
  5. 5.
    Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A (2017) Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 7:119–134.  https://doi.org/10.1177/2045125316681984 CrossRefPubMedGoogle Scholar
  6. 6.
    Bundesärztekammer (2017) Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger. www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/RL/Substitution.pdf. Zugegriffen: 28. Mai 2019Google Scholar
  7. 7.
    Center for Behavioral Health Statistics and Quality (CBHSQ) (2016) National survey on drug use and health: detailed tables. Substance abuse and mental health services administrations. SAMHSA, RockvilleGoogle Scholar
  8. 8.
    Deamer RL, Wilson DR, Clark DS, Prichard JG (2001) Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 20:7–14.  https://doi.org/10.1300/J069v20n04_02 CrossRefPubMedGoogle Scholar
  9. 9.
    Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al (2014) The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 109(8):1320–1333CrossRefGoogle Scholar
  10. 10.
    Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D (2016) A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of Opioid addiction. J Addict Med 10(2):93–103CrossRefGoogle Scholar
  11. 11.
    Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW (2008) A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165(2):179–187CrossRefGoogle Scholar
  12. 12.
    European Agency for the Evaluation of Medical Products (2001). EMEA public statement to suspend the marketing authorisation for Orlaam (levoacetylmethadol) in the European Union. EMEA/8776/01.Google Scholar
  13. 13.
    Fareed A, Vayalapalli S, Casarella J, Drexler K (2012) Effect of buprenorphine dose on treatment outcome. J Addict Dis 31:8–18CrossRefGoogle Scholar
  14. 14.
    US Food and Drug Administration (2016) Probuphine™ prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204442Orig1s000lbl.pdf Google Scholar
  15. 15.
    Greenwald MK, Comer SD, Fiellin DA (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 144:1–11CrossRefGoogle Scholar
  16. 16.
    Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000–2009CrossRefGoogle Scholar
  17. 17.
    Haasen C, Linden M, Tiberg F (2017) Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 78:22–29CrossRefGoogle Scholar
  18. 18.
    Haight BR, Learned SM, Laffont CM, Fudala J, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbrder C, RB-US-13-0001 Study Investigators (2019) Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393(10173):778–790.  https://doi.org/10.1016/S0140-6736(18)32259-1 CrossRefPubMedGoogle Scholar
  19. 19.
    Hser YI, Evans E, Huang D et al (2016) Long-term outcomes after randomization to buprenorphiine/naloxone versus methadone in a multi-site trial. Addiction 111:695–705CrossRefGoogle Scholar
  20. 20.
    Hser YI, Huang D, Saxon AJ et al (2017) Distinctine trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadone. J Addict Med 11:63–69CrossRefGoogle Scholar
  21. 21.
    Hser YI, Saxon AJ, Huang D et al (2014) Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 109:8–18Google Scholar
  22. 22.
    Itzoe M, Guarnieri M (2017) New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther 11:1429–1437.  https://doi.org/10.2147/DDDT.S109331 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750–2755CrossRefGoogle Scholar
  24. 24.
    Kenney SR, Anderson BJ, Bailey GL, Stein MD (2018) Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J Subst Abuse Treat 94:55–59.  https://doi.org/10.1016/j.jsat.2018.08.011 CrossRefPubMedGoogle Scholar
  25. 25.
    Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF (2016) Population Pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously Injectable, long-acting, sustained-release formulation of Buprenorphine, for the treatment of Opioid use disorder. J Clin Pharmacol 56:806–815CrossRefGoogle Scholar
  26. 26.
    Ling W, Charuvastra C, Collins JF et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475CrossRefGoogle Scholar
  27. 27.
    Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C (2019) Patient-centered outcomes in participants of a Buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, Multicenter, phase 3 study. J Addict Med.  https://doi.org/10.1097/ADM.0000000000000517 CrossRefPubMedGoogle Scholar
  28. 28.
    Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experience from around the world. J Addict Med 8:315–326CrossRefGoogle Scholar
  29. 29.
    Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S (2018) Weekly and monthly subcutaneous Buprenorhpine depot formulations vs daily Sublingual Burpenorphine with Naloxone for treatment of Opioid use disorder: a randomized clinical trial. JAMA Intern Med 178:764–773CrossRefGoogle Scholar
  30. 30.
    Mattick RP, Breen C, Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207.  https://doi.org/10.1002/14651858.CD002207.pub4 CrossRefPubMedGoogle Scholar
  31. 31.
    Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK (2014) A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 53:813–824CrossRefGoogle Scholar
  32. 32.
    Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C (2016) Sustained-release Buprenorphine (RBP-6000) blocks the effects of Opioid challenge with Hydromorphone in subjects with Opioid use disorder. J Clin Psychopharmacol 36:18–26.  https://doi.org/10.1097/JCP CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, Walter M, Seifritz E, Dürsteler KM, Herdener M (2019) One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction 114:103–111.  https://doi.org/10.1111/add.14442 CrossRefPubMedGoogle Scholar
  34. 34.
    Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, PRO-814 Study Group (2016) Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical traial. JAMA 316:282–290CrossRefGoogle Scholar
  35. 35.
    Rosenthal RN, Ling W, Casadonte P et al (2013) Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 108:2141–2149CrossRefGoogle Scholar
  36. 36.
    Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR (1997) Buprenorphine vs methadone maintenance treatment for concurrent opiod dependence and cocaine abuse. Arch Gen Psychiatry 54:713–720CrossRefGoogle Scholar
  37. 37.
    Schuckit MA (2016) Treatment of opioid-use disorders. N Engl J Med 375:1596–1597CrossRefGoogle Scholar
  38. 38.
    Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA (2019) Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. Clin Pharmacol Ther.  https://doi.org/10.1002/cpt.1406 CrossRefPubMedGoogle Scholar
  39. 39.
    Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H‑U (2017) Six-year outcome of Opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res 23(2):97–105CrossRefGoogle Scholar
  40. 40.
    Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 35(1):22–35CrossRefGoogle Scholar
  41. 41.
    Volkow ND, Frieden TR, Hyde PS, Cha SS (2014) Medication-Assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 370:2063–2066CrossRefGoogle Scholar
  42. 42.
    Walsh SL, Comer SD, Lofwall MR et al (2017) Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 74:894–902.  https://doi.org/10.1001/jamapsychiatry.2017.1874 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Walter M, Soyka M (2019) Opioide. In: Soyka M et al (Hrsg) Suchtmedizin. Elsevier, München, S 177–202CrossRefGoogle Scholar
  44. 44.
    White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 103:37–43.  https://doi.org/10.1016/j.drugalcdep.2009.03.008 CrossRefPubMedGoogle Scholar
  45. 45.
    Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, Scherbaum N (2009) Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation—results from a controlled clinical trial. Eur J Med Res 14:7–12CrossRefGoogle Scholar
  46. 46.
    Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, Scherbaum N (2009) A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 42:1–8.  https://doi.org/10.1055/s-0028-1083818 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität MünchenLMU MünchenMünchenDeutschland
  2. 2.Medical Park ChiemseeblickBernauDeutschland

Personalised recommendations